课题基金 / 基金详情

Low Dose Metronomic Chemotherapy as a Combination Strategy to Combat Innate or Acquired Resistance to Immune Checkpoint Therapy

Low Dose Metronomic Chemotherapy as a Combination Strategy to Combat Innate or Acquired Resistance to Immune Checkpoint Therapy
低剂量节律化疗作为对抗免疫检查点治疗先天性或获得性耐药性的组合策略
批准号：
410176
负责人：
Kerbel Robert S
金额：
$42.35万
依托单位：
Sunnybrook Research Institute (Toronto, Ontario)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2019
资助国家：
加拿大
项目状态：
已结题
起止时间：
2019-09-01 至 2023-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=410176&lang=en
关键词：
Acquired Resistance Combination Therapy Immune Checkpoint Inhibitors Innate Resistance Maintenance Therapy Metastatic Therapy Metronomic Chemotherapy New Preclinical Models Pd-L1

项目摘要

项目成果

Kerbel Robert S的其他基金

相似基金

相关文献

中文摘要
翻译
肿瘤学最新的重大进展是新药的显着成功，这些新药利用免疫系统治疗一些不同癌症的晚期转移疾病。这些药物中最重要的是免疫检查点抑制剂(ICI
英文摘要
The most significant recent advance in oncology is the remarkable success of new drugs which harness the immune system to treat advanced metastatic disease of a number of different cancers. Foremost among these drugs are "immune checkpoint inhibitor" (ICI
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preclinical approach to improve testing of immuno-oncology combination therapies for early or late stage metastatic disease
Translational studies of acquired resistance to antiangiogenic therapies undertaken in new preclinical models of locally advanced or metastatic cancer
海外基金